- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01293175
Whole Grain Polyphenol Bioavailability and Effects on Health
Whole Grain Polyphenol Bioavailability and Effects on Inflammatory, Oxidative and Hormonal Status
Study Overview
Detailed Description
Epidemiological evidence indicates that consumption of whole grains (WG) is associated with improved health and decreased risk for common chronic diseases. However there is paucity of intervention data regarding the beneficial effects of WG in vascular health and associated metabolic disorders.
From 2007 up to now five main intervention studies using WG were published. The results from these studies consistently showed no efficacy of WG to modify biochemical parameters in free-living subjects including WG in their habitual diet. Anyway some drawbacks could be found and mainly regarding subject compliance to the treatment and the type of WG-rich foods supplied.
Our working hypothesis is based on WG physiologically bioactive compounds mainly polyphenolic compounds such as ferulic acid (FA). FA is covalently bound to arabinoxylans constituting WG dietary fiber. This structure represents a natural way to carry polyphenol compounds, into the lower gut. A previous work indicated that intestinal microflora particularly Bifidobacteria and Lactobacilli is able to ferment WG polysaccharide moiety (prebiotic effect) and at the same time microbial esterases can release free phenolic acids. The free acids are adsorbed through the colon barrier into the blood. The slow and continuous release of phenolic acids, particularly FA, determines an increase of baseline level of FA in the blood of WG consumers. However no study correlated FA plasma concentration with health parameters such as biomarkers of inflammation, glucose metabolism and oxidative status which may be in turn associated to the CVD risk.
In this framework a controlled, parallel, two arm intervention study will be performed using a WG-rich product that will be selected from those commercially available for having a high content of FA (>500 mg/kg). The aim of this study is to evaluate the bioavailability of FA over a two month-treatment in overweight subjects and to correlate variation of FA plasma concentrations with biomarkers of oxidative (plasma antioxidant capacity, MDA) and inflammatory (CRP, anti- and pro-inflammatory cytokines) status, with nutritional status and with gastro-intestinal hormones related to appetite and glucose metabolism (ghrelin, PYY, PP, insulin, GLP-1, GIP and leptin). Eighty subjects will be selected in the respect of strict inclusion and exclusion criteria and will be randomized to include WG in opportunely revised individual habitual diet, or to continue with their habitual diet. At baseline, after 1 month and after 2 months from starting the protocol, blood drawings will be performed and urine and feces will be collected from fasting subjects. Gastro-intestinal hormone response and glucose metabolism following a standard meal will be also evaluated at baseline and at 2 months.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Portici, Italy, 80055
- Department of Food Science
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 - 60 years old, male and female
- Healthy by medical assessment
- Overweight: BMI > 25 and < 32 kg/m2
- Habitual diet characterized by i) absence of WG (all dietary carbohydrates derived from refined cereals); ii) absence of pro-biotics; iii) intake of dietary fibre ≤ 10 g/d; iv) intake of fruit and vegetables ≤ 2 portions/die; v)habit to have breakfast
- Sign of a written informed consent
Exclusion Criteria:
- Age < 18 and > 60 years old
- Pregnancy or breastfeeding
- Fasting plasma triglycerides ≥ 200 mg/dl and cholesterol > 200 mg/dl
- Cardiovascular events (AMI and/or stroke) in the last 6 months
- Regular intensive physical activity
- Hypertension
- Intestinal or metabolic diseases/disorders such as diabetic, renal, hepatic, pancreatic or ulcer
- Previous abdominal/gastrointestinal surgery
- Regular consumption of medication
- Antibiotic therapy within 2 months previous the study
- Food allergies and intolerances (celiac disease, lactose intolerance,)
- Concurrent participation or having participated in another clinical trial during the last 3 weeks
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Whole grains
Subjects will consume whole grains every day for two months
|
Subjects will consume whole grains at dose of 80 g/die, for two months
|
|
No Intervention: Control
Subjects will consume their habitual diet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Variation of serum polyphenol concentration
Time Frame: 1 year
|
Measure of serum polyphenol concentration (nmol/L)
|
1 year
|
|
Variation of plasma lipids
Time Frame: 1 year
|
Measure of plasma concentrations (mg/dL) of Total-, LDL-, and HDL-Cholesterol, as well as Triglycerides
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Variation of serum antioxidant capacity
Time Frame: 1 year
|
Measure of plasma FRAP (µmol/L) and MDA (µmol/L) concentrations.
|
1 year
|
|
Variation of body weight
Time Frame: 1 year
|
Measure of body weight (kg)
|
1 year
|
|
Variation of serum inflammatory marker concentration
Time Frame: 1 year
|
Measure of serum CRP, IL-6, TNF-α, PAI-1, Visfatin, Resistin concentration (pg/mL)
|
1 year
|
|
Variation of fecal microbiota composition
Time Frame: 1 year
|
By FISH (colony-forming unit, CFU/g)
|
1 year
|
|
Variation of serum gastro-intestinal hormone concentration
Time Frame: 1 year
|
It will be evaluated following a standard meal test.
In particular plasma response (pg/mL) of Ghrelin, PYY, Leptin, GIP, GLP-1, PP and insulin will be assessed
|
1 year
|
|
Variation of blood pressure
Time Frame: 1 year
|
Measure of blood pressure (mmHg)
|
1 year
|
|
Variation of body circumferences
Time Frame: 1 year
|
Measure of waist and hip circumferences (mm)
|
1 year
|
|
Variation of body composition
Time Frame: 1 year
|
Measure of body composition (% of lean and fat mass, % water)
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Vincenzo Fogliano, Prof, University of Naples
- Principal Investigator: Paola Vitaglione, Dr, University of Naples
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DSA-FF-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overweight
-
National University Health System, SingaporeActive, not recruitingObesity | Overweight and/or Obesity | Overweight or Obese Adults | Overweight , ObesitySingapore
-
Carmen Lucas AbellánUniversidad Católica San Antonio de MurciaCompletedOverweight/Obesity | Overweight or Obese | Overweight or Obese Adults | Obesity and Overweight | Obese SubjectsSpain
-
Empros Pharma ABNot yet recruitingOverweight or Obese | Obesity and Overweight
-
University of AarhusThe Danish Dairy Research Foundation, Denmark; Sygekassernes HelsefondCompletedOverweight and Obesity | Overweight Adolescents | Metabolic DiseaseDenmark
-
University Hospital Bispebjerg and FrederiksbergUniversity of CopenhagenCompleted
-
Children's Hospital Los AngelesEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruitingOverweight and Obesity | Overweight AdolescentsUnited States
-
University Hospital, LilleNational Research Agency, France; European Union; University of Lille Nord de... and other collaboratorsActive, not recruitingOverweight and Obesity | Overweight, Childhood | Overweight, InfantFrance
-
Medialis Ltd.RecruitingObesity & Overweight | Overweight (BMI > 25)United Kingdom
-
Holbaek SygehusUniversity of Copenhagen; University of Florida; University of Minnesota; Hebrew... and other collaboratorsRecruitingChildhood Overweight and ObesityDenmark
-
Federal University of Health Science of Porto AlegreCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.Active, not recruitingObesity & Overweight | Overweight (BMI > 25)Brazil
Clinical Trials on Whole grains
-
NYU Langone HealthCompletedHypertension | Obesity | Pregnancy Related | Diet Modification | Birth Weight | Blood Pressure | Pre-Eclampsia | Breast FeedingUnited States
-
Tufts UniversityTufts Medical Center; General MillsCompletedDigestive Health and Immune FunctionUnited States
-
USDA, Western Human Nutrition Research CenterCompletedFood PreferencesUnited States
-
The Cleveland ClinicNestléCompletedObesity | Overweight | Pre-diabeticUnited States
-
Lund UniversityRegion SkaneCompletedCardiovascular Diseases | Hypertension | Overweight | Diabetes Type 2 | Abdominal ObesitySweden
-
Cornell UniversityRecruitingBody Weight Changes | Body Composition ChangesUnited States
-
Yonsei UniversityCompleted
-
Yonsei UniversityCompletedImpaired Fasting Glucose | Newly Diagnosed Type 2 DiabetesKorea, Republic of
-
University of California, San DiegoSuspendedA Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With ObesityObesity | Insulin ResistanceUnited States
-
Plexus WorldwideGeorge Mason UniversityUnknown